Respiratory viruses, especially influenza A virus, are seasonal sources of morbidity and mortality both in the United States and globally ([@bb0010], [@bb0005], [@bb0015]). The 2009 H1N1 Influenza A pandemic illustrated the importance of diagnostics to detect and identify respiratory viruses, and in general, accurate diagnostics are important in infectious disease management, making treatment decisions, and for novel pathogen discovery ([@bb0010], [@bb0005], [@bb0015]).

Viral diagnostics have migrated from culture to rapid and molecular methodologies, and more laboratories are utilizing these methods ([@bb0010], [@bb0005]). Respiratory virus diagnostics, such as culture, immunologic techniques, sequencing, and molecular diagnostics, have advantages and disadvantages. Culture has low complexity but also low sensitivity and requires viable organism. Immunologic techniques like direct fluorescent antibody (DFA) are rapid but can be laborious and have lower sensitivity than molecular diagnostics. Sequencing provides substantial information but is technically complex and impractical. Molecular diagnostics, although fairly complex, are becoming the preferred technology because of high sensitivity and shorter testing time.

Reverse-transcriptase polymerase chain reaction/electrospray ionization mass spectrometry (RT-PCR/ESI-MS) technology is a highly complex technology that provides accurate diagnostic information for respiratory viruses, particularly influenza A ([@bb0020], [@bb0025], [@bb0030], [@bb0035], [@bb0040], [@bb0045], [@bb0050], [@bb0055], [@bb0060]).

Performance evaluations of RT-PCR/ESI-MS for respiratory virus detection have been performed, notably by [@bb0020], [@bb0025], [@bb0040], [@bb0055]. We expanded on these studies utilizing retrospectively collected waste nasopharyngeal swabs (NPs) and compared PLEX-ID RT-PCR/ESI-MS RVS 2.5 kit (Abbott Molecular, Des Plaines, IL, USA) results to both combined DFA and xTAG Respiratory Virus Panel (xTAG RVP) (Luminex Corporation, Austin, TX, USA) results as well as DFA and xTAG RVP individually, to determine percent agreement, sensitivity, specificity, and kappa for RVS 2.5.

As part of an institutional review board--approved study, waste NPs and their test results, DFA or xTAG RVP, were collected from clinical virology from 10/2011 to 2/2013. Samples were selected with a positive:negative test result ratio of 1:1 (N = 244, positive n = 122, negative n = 122). All samples were initially tested by DFA (total N = 244, positive n = 44, negative n = 200); DFA negative samples were tested with xTAG RVP only if the patient was immunocompromised. xTAG RVP screening of immunocompromised patients yielded additional positive samples (n = 78) for comparison with RT-PCR/ESI-MS. The remaining samples (n = 122) were negative by either DFA only for non-immunocompromised individuals or negative by DFA and xTAG RVP for immunocompromised individuals.

Nucleic acid extraction was performed utilizing the Arrow (NorDiag, Oslo, Norway) per manufacturer's instructions. The Broad Respiratory Virus Surveillance Kit version 2.5 (RVS 2.5) and PLEX-ID were utilized for amplification and analysis per manufacturer's instructions. Positive reactions were defined as respiratory virus identification with a Q score ≥0.9, and results were compared to the reported diagnostic result, either DFA or xTAG RVP for determination of percent agreement, sensitivity, specificity, and kappa. All positive sample types were considered negative for specificity purposes for other viruses, i.e., samples respiratory syncytial virus (RSV) positive but influenza A/B negative were considered negative for calculating influenza specificity. Discordant testing was not performed due to sample and nucleic acid extract volume limitations.

Positive samples consisted of: 34% influenza (n = 42, influenza A = 37, influenza B = 5), 26% RSV (n = 32), 15% coronavirus (n = 18), 11% metapneumovirus (n = 13), 9% parainfluenza virus 1--3 (n = 11) and 5% adenovirus (n = 6).

By test, positive percent agreement was 93.2% (41/44) and 89.7% (70/78) for DFA and xTAG RVP, respectively. These results and positive percent agreement by specific virus are summarized in [Table 1](#t0005){ref-type="table"} .Table 1Positive percent agreement and percent agreement by virus and by reference method, DFA, and xTAG RVP PCR.Reference testReference test resultRVS 2.5 resultPercent agreementDFA444193.2% (41/44)xTAG RVP PCR787089.7% (70/78)Total12211191% (111/122)Influenza DFA171694.1% (17/18)Influenza xTAG RVP PCR252392% (23/25)Total423992.9% (39/42)RSV DFA181794.4% (17/18)RSV xTAG RVP PCR141392.9% (13/14)Total323093.8% (30/32)Coronavirus DFA00 (2[a](#tf0005){ref-type="table-fn"})NACoronavirus xTAG RVP PCR181794.4% (17/18)Total181794.4% (17/18)Metapneumovirus DFA44100% (4/4)Metapneumovirus xTAG RVP PCR9888.8% (8/9)Total131292.3% (12/13)Parainfluenza virus 1--3 DFA43 (1[a](#tf0005){ref-type="table-fn"})75% (3/4)Parainfluenza virus 1--3 xTAG RVP PCR7457.1% (4/7)Total11763.6% (7/11)Adenovirus DFA11 (2[a](#tf0005){ref-type="table-fn"})100% (1/1)Adenovirus xTAG RVP PCR55100% (5/5)Total66100% (6/6)[^1]

DFA and xTAG RVP were also utilized as gold standards to calculate sensitivity and specificity, overall, and by virus for RVS 2.5 ([Table 2](#t0010){ref-type="table"} ).Table 2Sensitivity, specificity, and kappa analysis for RVS 2.5 compared to combined DFA and xTAG RVP as gold standard assays.PathogenSensitivity (n)Specificity (n)[a](#tf0010){ref-type="table-fn"}Kappa (95% CI)All91.0% (111/122)95.1% (116/122)0.86 (0.79--0.92)Influenza92.9% (39/42)100% (202/202)0.96 (0.91--1)RSV93.8% (30/32)99.5% (211/212)0.95 (0.88--1)Coronavirus94.4% (17/18)99% (224/226)0.91 (0.81--1)Metapneumovirus92.3% (12/13)100% (231/231)0.96 (0.88--1)Parainfluenza 1--363.6% (7/11)99.5% (231/233)0.69 (0.44--0.93)Adenovirus100% (6/6)99.0% (236/238)0.85 (0.65--1)[^2]

RVS 2.5 results compared well to DFA and xTAG RVP. Overall agreement was 93% (227/244, kappa = 0.86, 95% confidence interval \[CI\]: 0.79--0.92); overall positive and negative agreement were both \>90%. DFA and xTAG RVP were utilized as gold standard assays; sensitivity and specificity were both \>90% for RT-PCR/ESI-MS compared to DFA and xTAG RVP. By virus, all percent agreements, sensitivities, and specificities were \>90%. However, parainfluenza virus 1--3 had overall agreement and sensitivity of 63.4% (7/11). A limited number of parainfluenza 1--3 positives (n = 11) evaluated contributed to this; it does not appear that sample quality or volume was an issue because if this were the case, the results would be affected across all positive samples. The parainfluenza 1--3 false negatives as well as other false-negative results from the study were potentially because of the quantity of virus in the sample tested was below the limit of detection of 150 copies per well for all viruses the RVS primers amplify ([@bb0025]).

The results here are similar to [@bb0020], [@bb0025] and [@bb0040]. Chen et al. utilized RVS 2.0; Forman et al. and this evaluation employed RVS 2.5. Sensitivity and specificity improved from 89.1% and 80.3%, respectively, to 91% and 95.1%, respectively, compared to [@bb0020]. Positive percent agreement improved from 77.9% to 91% compared to [@bb0025]. This study reports higher agreement for metapneumovirus than [@bb0040], at 92.3%, although this study evaluated fewer metapneumovirus positives (n = 13).

Nucleic acid extraction methodology utilized here differed between this study and [@bb0020], [@bb0025] and [@bb0040] and possibly contributed to sensitivity and specificity improvements.

Despite numerous limitations to the study, the results presented here add additional performance characteristic information to previously published studies that utilized RT-PCR/ESI-MS for the detection and identification of respiratory viruses ([@bb0030], [@bb0035], [@bb0050], [@bb0055], [@bb0060]).

Few samples positive for coronavirus, metapneumovirus and adenovirus were tested. No further analysis was performed on discrepant results due to low sample and nucleic acid extract volumes after RT-PCR/ESI-MS testing was completed. This was especially the case for the DFA-negative/RT-PCR/ESI-MS--positive samples ([Table 1](#t0005){ref-type="table"}). Comparison of DFA with RT-PCR/ESI-MS was problematic because comparison of a non-amplified diagnostic, DFA, with an amplified diagnostic, RT-PCR/ESI-MS, may have skewed the RT-PCR/ESI-MS performance characteristics. Additionally, all of the xTAG RVP--positive results were initially DFA negative, and this discrepancy was also problematic. Additionally, DFA could have generated false-positive results, as 3 DFA-positive detections were not confirmed by RT-PCR/ESI-MS or xTAG RVP. A more accurate comparison would have utilized 2 amplified tests, such as xTAG RVP and type specific real-time PCR. Although DFA comparison was suboptimal, it was the best available comparison method based on clinical virology screening algorithms used to report respiratory virus diagnoses. Finally, xTAG RVP assay was only performed on DFA-negative samples collected among immunocompromised patient negatives as per clinical virology testing algorithm policy. Many DFA-negative samples collected among immunocompetent patients could have tested positive with xTAG RVP. Additionally, the DFA negative, RT-PCR/ESI-MS false positives ([Table 1](#t0005){ref-type="table"}.) could have been more accurately confirmed if RT-PCR/ESI-MS and xTAG RVP had been directly compared for those samples.

RT-PCR/ESI-MS technology demonstrated the capability to detect and identify respiratory viruses when compared to DFA and xTAG RVP, and all have utility in screening NP samples for respiratory viruses. Based on the limitations associated with this study, further evaluations of RT-PCR/ESI-MS technology, including prospective analysis and comparison with multiple molecular methods, will be required before clinical implementation.
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[^1]: Indicates a false-positive result defined as a result that was positive utilizing the PLEX-ID RVS 2.5 kit and negative by DFA.

[^2]: Calculated using all non-virus positives as negative. For example, samples positive for RSV were considered negative for influenza virus.
